链接：https://www.abinscience.cn/product/40/4315.html
名称：Anti-Human CD16a/FCGR3A Antibody (NM3E2)
货号：HY386207
种属反应性：Human
宿主：Human
形式：Liquid
纯度：>95% as determined by SDS-PAGE.
克隆性：Monoclonal
同种型：IgG1, kappa
应用：FCM
Accession号：P08637
靶点：CD16a, CD16A, FCGR3A, Fc-gamma RIII-alpha, FcRIIIa, IgG Fc receptor III-2, Low affinity immunoglobulin gamma Fc region receptor III-A, IGFR3, CD16a antigen, Fc-gamma RIII, FCGR3, Fc-gamma RIIIa, FCG3, FcRIII, FcR-10
用途范围：仅用于科研
储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
产品介绍：Anti-Human CD16a/FCGR3A Antibody (NM3E2) 是abinScience推出的高特异性人源单克隆抗体。该抗体靶向人CD16a（FcγRIIIa），这是一种在自然杀伤（NK）细胞、巨噬细胞和中性粒细胞上表达的关键免疫球蛋白Fc段受体，参与抗体依赖性细胞介导的细胞毒性（ADCC）等免疫反应。本品克隆号为NM3E2，采用Protein A/G从细胞培养上清中纯化，纯度超过95%，经严格验证适用于流式细胞术（FCM），是研究免疫细胞分型、功能及相关疾病机制的理想工具。其高亲和力与低批间差异，为免疫学和肿瘤免疫治疗研究提供了可靠、一致的数据保障。
产品购买联系方式：027-87433958/17302791434
邮箱：info@abinscience.com
参考文献：
CD16A Shedding Regulates Innate Cell Engager-Induced Serial Killing by Natural Killer Cells. PMID: 41116262
High-affinity CD16A polymorphism associated with reduced risk ofsevere COVID-19. PMID: 40402577
Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy. PMID: 30786043
CD16a pairs form the basal molecular subunit for the NK-cell ADCC lytic synapse. PMID: 40570099
Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody. PMID: 40574860
The novel CD16A/anti-CD3 bifunctional protein, eCD16A/anti-CD3-BFP, redirects T cell cytotoxicity toward antibody-bound target cells. PMID: 39763374
Evidence for CD16a-Mediated NK Cell Stimulation in Antibody-Mediated Kidney Transplant Rejection. PMID: 27906829
CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells. PMID: 29514797
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells. PMID: 39053944
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. PMID: 29576375
The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity. PMID: 29733746
FcγR Binding and ADCC Activity of Human IgG Allotypes. PMID: 32435243
FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma. PMID: 25050883
Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis. PMID: 37149714
Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta-analysis. PMID: 37114884
Polymorphism of FCGR3A gene in chronic beryllium disease. PMID: 30245507
FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. PMID: 27282998
Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism. PMID: 37804003
Functional FCGR3A 158 V/F and IL-6 -174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis. PMID: 24728031
FCGR2A, FCGR3A, FCGR3B polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis. PMID: 26314337
FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population. PMID: 39175948
FCGR3A V158F gene polymorphism and trastuzumab response in HER2-positive breast cancer patients. PMID: 39472454
FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer. PMID: 26363448
The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis. PMID: 27431582
Associations between FCGR2A rs1801274, FCGR3A rs396991, FCGR3B NA1/NA2 polymorphisms and periodontitis: a meta-analysis. PMID: 23649770
FCGR3A gene duplication, FcgammaRIIb-232TT and FcgammaRIIIb-HNA1a associate with an increased risk of vertical acquisition of HIV-1. PMID: 36084039
FCGR3A and FCGR2A Genotypes Differentially Impact Allograft Rejection and Patients' Survival After Lung Transplant. PMID: 31249568
FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder. PMID: 38579568
Associations between functional FCGR2A R131H and FCGR3A F158V polymorphisms and responsiveness to TNF blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis. PMID: 27490376
The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity. PMID: 29733746
FcγR Binding and ADCC Activity of Human IgG Allotypes. PMID: 32435243
Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. PMID: 19700393
Analysis of FCGR3A-p.176Val variants in women with recurrent pregnancy loss and the association with CD16a expression and anti-HLA antibody status. PMID: 36997584
详情请咨询 abinScience 亚洲区官方子公司 —— 武汉艾必赛生物技术有限公司
武汉艾必赛生物技术有限公司成立于 2023 年，是 abinScience 在亚洲地区设立的官方全资子公司，全面负责 abinScience 品牌在亚太市场的科研试剂推广、销售及技术支持工作。
依托严格的产品研发体系和国际化的质量管理标准，武汉艾必赛与 AtaGenix、ProteoGenix 等知名品牌保持长期战略合作，现已构建起涵盖抗体、重组蛋白、工具酶、试剂盒、实验耗材在内的多品类供应体系，面向区域内科研机构、高校实验室与生物医药企业，提供稳定、高效、可信赖的产品与服务。
核心业务覆盖：
? 抗体产品（单抗、多抗、重组抗体等）
? 蛋白与多肽试剂（标签蛋白、功能蛋白等）
? 分子与细胞实验相关耗材
? 定制化研发服务（蛋白表达、抗体定制、亲和力成熟等）
? 科研供应链整合与项目配套支持
武汉艾必赛始终秉持“Empowering Bioscience Discovery”的理念，为亚太地区的生命科学研究持续注入高质量动能。
返回顶部
